Mineralys Therapeutics (MLYS) Stock Analysis

What Mineralys Therapeutics does

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Key metrics

ETFs linked to MLYS

Broad-market and Healthcare sector ETFs an investor holding Mineralys Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how MLYS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Mineralys Therapeutics?

Mineralys Therapeutics trades under the ticker MLYS on NASDAQ.

Which exchange is MLYS listed on?

MLYS is listed on NASDAQ.

What sector does Mineralys Therapeutics operate in?

Mineralys Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze MLYS in a portfolio?

PortView shows MLYS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.